Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?

Eur Urol. 2015 Nov;68(5):802-4. doi: 10.1016/j.eururo.2015.04.019. Epub 2015 Apr 24.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Androgen Receptor Antagonists / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Benzamides
  • Bone Neoplasms / drug therapy*
  • Docetaxel
  • Humans
  • Male
  • Neoplasm Recurrence, Local / blood*
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives*
  • Phenylthiohydantoin / therapeutic use
  • Prostatectomy*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Taxoids / therapeutic use*

Substances

  • Androgen Receptor Antagonists
  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Benzamides
  • Nitriles
  • Taxoids
  • Docetaxel
  • Phenylthiohydantoin
  • enzalutamide